Role of heart rate as a marker and mediator of poor outcome for patients with heart failure

Current Heart Failure Reports

Volumn 9, Issue 2, 2012, Pages 133-138

  Kapoor, John R ^a   Heidenreich, Paul A ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Beta blockers; Heart failure; Heart rate; Hospitalization; Ivabradine; Management; Mortality; Pharmaceuticals; Pharmacotherapy; Risk factors; Tachycardia

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; IVABRADINE; PLACEBO; ANTIARRHYTHMIC AGENT; BENZAZEPINE DERIVATIVE;

ARTICLE; CARDIOVASCULAR RISK; CHRONOTROPISM; CORONARY ARTERY DISEASE; DISEASE MARKER; HEART FAILURE; HEART MUSCLE CELL; HEART RATE; HEART VENTRICLE FIBRILLATION; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; SYSTOLIC DYSFUNCTION; TACHYCARDIA; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANTI-ARRHYTHMIA AGENTS; BENZAZEPINES; HEART FAILURE; HEART RATE; HUMANS; PROGNOSIS; TACHYCARDIA;

EID: 84864885294     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-012-0086-8     Document Type: Article

References (55)

1. Palatini P, Casiglia E, Julius S, et al. High heart rate: a risk factor for cardiovascular death in elderly men. Arch Intern Med. 1999;159:585-92. (Pubitemid 29133883)
2. Kannel WB, Kannel C, Paffenbarger Jr RS, et al. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J. 1987;113:1489-94. (Pubitemid 17092823)
3. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807-16. This randomized trial found that ivabradine did not reduce mortality and cardiac events for all patients, but appeared to be effective in the subgroup with a heart rate above 70 bpm.
4. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebocontrolled study. Lancet. 2010;376: 875-85. This randomized trial of ivabradine confirmed the substudy findings of BEAUTIFUL in that it only included those with a heart rate above70 bpm and found reduced cardiac events in patients with heart failure. The reduction in events was largely due to reduced heart failure hospitalizations and heart failure death.
5. Shinbane JS, Wood MA, Jensen DN, et al. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol. 1997;29:709-15. (Pubitemid 27128241)
6. Moe GW, Armstrong P. Pacing-induced heart failure: a model to study the mechanism of disease progression and novel therapy in heart failure. Cardiovasc Res. 1999;42:591-9. (Pubitemid 29298127)
7. Yarbrough WM, Spinale FG. Large animal models of congestive heart failure: a critical step in translating basic observations into clinical applications. J Nucl Cardiol. 2003;10:77-86. (Pubitemid 36335856)
8. Nagatsu M, Spinale FG, Koide M, et al. Bradycardia and the role of beta-blockade in the amelioration of left ventricular dysfunction. Circulation. 2000;101:653-9. (Pubitemid 30094737)
9. Schulz R, Aker S, Belosjorow S, et al. Stress kinase phosphorylation is increased in pacing-induced heart failure in rabbits. Am J Physiol Heart Circ Physiol. 2003;285:H2084-90. (Pubitemid 37305950)
10. Heusch P, Canton M, Aker S, et al. The contribution of reactive oxygen species and p38 mitogen activated protein kinase to myofilament oxidation and progression of heart failure in rabbits. Br J Pharmacol. 2010;160:1408-16.
11. Mulder P, Barbier S, Chagraoui A, et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation. 2004;109:1674-9. (Pubitemid 38451726)
12. Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol. 1986;57:563-70. (Pubitemid 16015939)
13. Thackray SD, Ghosh JM, Wright GA, et al. The effect of altering heart rate on ventricular function in patients with heart failure treated with beta-blockers. Am Heart J. 2006;152:713.
14. Helmer GA, McKirnan MD, Shabetai R, et al. Regional deficits of myocardial blood flow and function in left ventricular pacinginduced heart failure. Circulation. 1996;94:2260-7. (Pubitemid 26360523)
15. Cesseli D, Jakoniuk I, Barlucchi L, et al. Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ Res. 2001;89:279-86. (Pubitemid 34132687)
16. Ahmadi-Kashani M, Kessler DJ, Day J, et al. Heart rate predicts outcomes in an implantable cardioverter-defibrillator population. Circulation. 2009;120:2040-5.
17. Böhm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010;376: 886-94. This substudy of the SHIFT trial found that patients with the highest heart rates (≥87 bpm) were at more than twofold higher risk for cardiac events than were patients with the lowest heart rates (70 to <72 bpm). The risk of cardiac events increased by 3% with every beat increase from baseline heart rate and 16% for every 5-bpm increase.
18. Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008;372: 817-21. This substudy of the BEAUTIFUL trial found that patients with a heart rate above 70 were at increased risk of death, heart failure, and coronary events. The relationship with elevated heart rate was stronger for heart failure events than for coronary events.
19. Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation. 1997;95:2660-7. (Pubitemid 27255495)
20. Poole-Wilson PA, Uretsky BF, Thygesen K, et al. Mode of death in heart failure: findings from the ATLAS trial. Heart. 2003;89:42-8. (Pubitemid 36044288)
21. Lechat P, Hulot J-S, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation. 2001;103:1428-33. (Pubitemid 32220636)
22. Liao L, Jollis JG, Anstrom KJ, et al. Costs for heart failure with normal vs. reduced ejection fraction. Arch Intern Med. 2006;166:112e8.
23. Kapoor JR, Heidenreich PA. Heart rate predicts mortality in patients with heart failure and preserved systolic function. J Card Fail. 2010;16(10):806-11.
24. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005;26:967e74.
25. Jouven X, Empana J-P, Schwartz PJ, et al. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med. 2005;352:1951e8.
26. Beere PA, Glagov S, Zarins CK. Retarding effect of lowered heart rate on coronary atherosclerosis. Science. 1984;226:180e2.
27. Beere PA, Glagov S, Zarins CK. Experimental atherosclerosis at the carotid bifurcation of the cynomolgus monkey: localization, compensatory enlargement, and the sparing effect of lowered heart rate. Arterioscler Thromb. 1992;12:1245e53.
28. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation. 2001;104:1477e82.
29. Perski A, Olsson G, Landou C, et al. Minimum heart rate and coronary atherosclerosis: independent relations to global se verity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. Am Heart J. 1992;123:609e16.
30. Mangoni AA, Mircoli L, Giannattasio C, et al. Heart ratedependence of arterial distensibility in vivo. J Hypertens. 1996;14:897-901. (Pubitemid 26237211)
31. Sa Cunha R, Pannier B, Benetos A, et al. Association between high heart rate and high arterial rigidity in normotensive and hypertensive subjects. J Hypertens. 1997;15:1423-30. (Pubitemid 28039570)
32. Hedblad B, Wikstrand J, Janzon L, et al. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation. 2001;103:1721e6.
33. Festa A, D'Agostino Jr R, Hales CN, et al. Heart rate in relation to insulin sensitivity and insulin secretion in nondiabetic subjects. Diabetes Care. 2000;23:624e8.
34. Schwartz PJ, Priori SG. Sympathetic nervous system and cardiac arrhythmias. In: Zipes DP, Jalife J, editors. Cardiac electrophysiology: from cell to bedside. Philadelphia: WBSaunders Co; 1990. p. 330e343.
35. Hohnloser SH, Klingenheben T, van de Loo A, et al. Reflex versus tonic vagal activity as a prognostic parameter in patients with sustained ventricular tachycardia or ventricular fibrillation. Circulation. 1994;89:1068e73.
36. Tanaka N, Nozawa T, Yasumura Y, et al. Heart-rate-proportional oxygen consumption for constant cardiac work in dog heart. Jpn J Physiol. 1990;40:503-21.
37. Hasenfuss G, Holubarsch C, Hermann HP, et al. Influence of the force-frequency relationship on haemodynamics and left ventricular function in patients with non-failing hearts and in patients with dilated cardiomyopathy. Eur Heart J. 1994;15:164-70. (Pubitemid 24110691)
38. Kurita T, Onishi K, Dohi K, et al. Impact of heart rate on mechanical dyssynchrony and left ventricular contractility in patients with heart failure and normal QRS duration. Eur J Heart Fail. 2007;9:637-43. (Pubitemid 46705570)
39. Sambuceti G, Marzilli M, Marraccini P, et al. Coronary vasoconstriction during myocardial ischemia induced by rises in metabolic demand in patients with coronary artery disease. Circulation. 1997;95:2652-9. (Pubitemid 27255494)
40. Reynolds RD, Calzadilla SV, Lee RV. Spontaneous heart rate, propranolol, and ischaemia-induced ventricular fibrillation in the dog. Cardiovasc Res. 1978;12:653-8. (Pubitemid 9127617)
41. La Rovere MT, Pinna GN, Hohnloser SH, et al. Baroreflex sensitività and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation. 2001;103:2072-7. (Pubitemid 32373010)
42. Mulder P, Barbier S, Chagroui A, et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation. 2004;109:1674-9. (Pubitemid 38451726)
43. Bolli R, Fisher DJ, Entman ML. Factors that determine the occurrence of arrhythmias during acute myocardial infarction. Am Heart J. 1986;111:261-70. (Pubitemid 16107263)
44. Aupetit JF, Frassati D, Bui-Xuan B, et al. Efficacy of a betaadrenergic receptor antagonist, propranolol, in preventing ischaemic ventricular fibrillation: dependence on heart rate and ischaemia duration. Cardiovasc Res. 1998;37:646-55. (Pubitemid 28231159)
45. Kjekshus J, Gullestad L. Heart rate as a therapeutic target in heart failure. Eur Heart J Suppl. 1999;1(Suppl H):H64-9. (Pubitemid 29304286)
46. Yamakawa H, Takeuchi M, Takaoka H, et al. Negative chronotropic effect of -blockade therapy reduces myocardial oxygen expenditure for nonmechanical work. Circulation. 1996;94:340-5. (Pubitemid 26266117)
47. Thackray SDR, Ghosh JM, Wright GA, et al. The effect of altering heart rate on ventricular function in patients with heart failure treated with B-blockers. Am Heart J. 2006;152:713.e9-713.e13.
48. Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol. 2008;101:865-9.
49. Gullestad L, Wikstrand J, Deedwania P, et al. What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). J Am Coll Cardiol. 2005;45:252-9. (Pubitemid 40094734)
50. Metra M, Torp-Pedersen C, Swedberg K, et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J. 2005;26:2259-68. (Pubitemid 41541389)
51. McAlister FA, Wiebe N, Ezekowitz JA, et al. Meta-analysis: betablocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150:784-94.
52. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation. 1998;98:1329-34. (Pubitemid 28443398)
53. Lechat P, Escolano S, Golmard JL, et al. Prognostic value of bisoprolol induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). Circulation. 1997;96:2197-205. (Pubitemid 27425823)
54. Fox K, Ford I, Steg PG, et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J. 2009;30:2337-45.
55. Palatini P, Julius S. The physiological determinants and risk correlations of elevated heart rate. Am J Hypertens. 1999;12:3S-8S. (Pubitemid 29118370)